PMID- 28768346
OWN - NLM
STAT- MEDLINE
DCOM- 20180530
LR  - 20180530
IS  - 1439-3522 (Electronic)
IS  - 0720-4299 (Linking)
VI  - 85
IP  - 7
DP  - 2017 Jul
TI  - [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: 
      Possibilities and Challenges].
PG  - 383-392
LID - 10.1055/s-0043-103085 [doi]
AB  - Background Recently, scientific interest in the therapeutic potential of 
      serotonergic and psilocybin hallucinogens (psychedelics) such as lysergic acid 
      diethylamide (LSD) and entactogens like 3,4-methylendioxymethamphetamine (MDMA) 
      within the framework of psychotherapy has resumed. The present article provides 
      an overview on the current evidence on substance-assisted psychotherapy with 
      these substances. Method A selective search was carried out in the PubMed and 
      Cochrane Library including studies investigating the clinical use of serotonergic 
      psychoactive substances since 2000. Results Studies were found investigating the 
      following indications: alcohol (LSD and psilocybin) and tobacco addiction 
      (psilocybin), anxiety and depression in patients suffering from life-threatening 
      somatic illness (LSD and psilocybin), obsessive-compulsive disorder (OCD) 
      (psilocybin), treatment-resistant major depression (psilocybin), and 
      posttraumatic stress disorder (PTSD) (MDMA). Discussion Substance use disorders, 
      PTSD and anxiety and depression in patients suffering from life-threatening 
      somatic illness belong to the indications with the best evidence for 
      substance-assisted psychotherapy with serotonergic psychoactive agents. To date, 
      studies indicate efficacy and relatively good tolerability. Further studies are 
      needed to determine whether these substances may represent suitable and effective 
      treatment options for some treatment-resistant psychiatric disorders in the 
      future.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Majic, Tomislav
AU  - Majic T
AD  - Psychiatrische Universitatsklinik der Charite im St. Hedwig Krankenhaus, Charite 
      Universitatsmedizin Berlin, Charite Campus Mitte, Berlin.
FAU - Jungaberle, Henrik
AU  - Jungaberle H
AD  - FINDER Institut fur Praventionsforschung, Berlin.
FAU - Schmidt, Timo T
AU  - Schmidt TT
AD  - Bernstein Center for Computational Neuroscience, Berlin.
FAU - Zeuch, Andrea
AU  - Zeuch A
AD  - DRK Westend, Spandauer Damm 130, Klinik fur Anasthesie, Schmerztherapie, 
      Intensiv- und Notfallmedizin, Berlin.
FAU - Hermle, Leo
AU  - Hermle L
AD  - Klinik fur Psychiatrie und Psychotherapie, Christophsbad, Goppingen.
FAU - Gallinat, Jurgen
AU  - Gallinat J
AD  - Universitatsklinikum Hamburg-Eppendorf, Klinik und Poliklinik fur Psychiatrie und 
      Psychotherapie, Hamburg.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Psychotherapie mit adjuvanter Gabe von serotonergen psychoaktiven Substanzen - 
      Moglichkeiten und Hindernisse.
DEP - 20170802
PL  - Germany
TA  - Fortschr Neurol Psychiatr
JT  - Fortschritte der Neurologie-Psychiatrie
JID - 8103137
RN  - 0 (Hallucinogens)
RN  - 0 (Serotonin Agents)
RN  - 2RV7212BP0 (Psilocybin)
RN  - 8NA5SWF92O (Lysergic Acid Diethylamide)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Combined Modality Therapy
MH  - Hallucinogens/*therapeutic use
MH  - Humans
MH  - Lysergic Acid Diethylamide/therapeutic use
MH  - Mental Disorders/*drug therapy/*therapy
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*therapeutic use
MH  - Psilocybin/therapeutic use
MH  - Psychotherapy/*methods
MH  - Serotonin Agents/*therapeutic use
MH  - Treatment Outcome
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2017/08/03 06:00
MHDA- 2018/05/31 06:00
CRDT- 2017/08/03 06:00
PHST- 2017/08/03 06:00 [entrez]
PHST- 2017/08/03 06:00 [pubmed]
PHST- 2018/05/31 06:00 [medline]
AID - 10.1055/s-0043-103085 [doi]
PST - ppublish
SO  - Fortschr Neurol Psychiatr. 2017 Jul;85(7):383-392. doi: 10.1055/s-0043-103085. 
      Epub 2017 Aug 2.